Funakoshi S, Taub D D, Anver M R, Raziuddin A, Asai O, Reddy V, Rager H, Fanslow W C, Longo D L, Murphy W J
Laboratory of Leukocyte Biology, National Cancer Institute, Frederick Cancer Research and Development Center (NCI-FCRDC), Maryland 21702, USA.
J Clin Invest. 1997 Feb 1;99(3):484-91. doi: 10.1172/JCI119183.
CD40 is a molecule present on multiple cell types including B lymphocyte lineage cells. CD40 has been shown to play an important role in B cell differentiation and activation in vitro, although little is known concerning the effects of CD40 stimulation in vivo. We therefore examined the effects of CD40 stimulation in mice using a syngeneic bone marrow transplantation (BMT) model in an effort to augment B cell recovery after high dose therapy with hematopoietic reconstitution. After the BMT, mice were treated with or without 2-6 microg of a soluble recombinant murine CD40 ligand (srmCD40L) given intraperitoneally twice a week. A significant increase in B cell progenitors (B220+/ surface IgM-) was observed in the bone marrow of mice receiving the srmCD40L. The treated recipients also demonstrated improved B-cell function with increases in total serum immunoglobulin and increased splenic mitogen responsiveness to LPS being noted. Additionally, srmCD40L treatment promoted secondary lymphoid organ repopulation, accelerating germinal center formation in the lymph nodes. Total B cell numbers in the periphery were not significantly affected even with continuous srmCD40L administration. Lymphocytes obtained from mice treated with the ligand also had increases in T cell mitogen and anti-CD3 mAb responsiveness and acquired the capability to produce IL-4. Surprisingly, treatment with srmCD40L also produced hematopoietic effects in mice, resulting in an increase of BM and splenic hematopoietic progenitor cells in the mice after BMT. Treatment with srmCD40L significantly increased granulocyte and platelet recovery in the peripheral blood. Incubation of BMC with srmCD40L in vitro also resulted in increased progenitor proliferation, demonstrating that the hematopoietic effects of the ligand may be direct. Thus, stimulation of CD40 by its ligand may be beneficial in accelerating both immune and hematopoietic recovery in the setting of bone marrow transplantation.
CD40是一种存在于多种细胞类型(包括B淋巴细胞系细胞)上的分子。尽管关于CD40刺激在体内的作用知之甚少,但CD40已被证明在体外B细胞分化和激活中起重要作用。因此,我们使用同基因骨髓移植(BMT)模型研究了CD40刺激对小鼠的影响,以期在高剂量治疗后促进造血重建时增强B细胞恢复。BMT后,对小鼠进行每周两次腹腔注射2 - 6微克可溶性重组鼠CD40配体(srmCD40L)或不进行该处理。在接受srmCD40L的小鼠骨髓中观察到B细胞祖细胞(B220 + /表面IgM -)显著增加。接受治疗的受体还表现出B细胞功能改善,总血清免疫球蛋白增加,脾脏对LPS的丝裂原反应性增强。此外,srmCD40L治疗促进了次级淋巴器官的重新填充,加速了淋巴结中生发中心的形成。即使持续给予srmCD40L,外周血中的总B细胞数量也未受到显著影响。从用该配体治疗的小鼠中获得的淋巴细胞对T细胞丝裂原和抗CD3单克隆抗体的反应性也增加,并获得了产生IL - 4的能力。令人惊讶的是,srmCD40L治疗在小鼠中还产生了造血作用,导致BMT后小鼠骨髓和脾脏造血祖细胞增加。srmCD40L治疗显著增加了外周血中粒细胞和血小板的恢复。体外将骨髓细胞与srmCD40L孵育也导致祖细胞增殖增加,表明该配体的造血作用可能是直接的。因此,其配体对CD40的刺激可能有利于加速骨髓移植情况下的免疫和造血恢复。